Bempedoic acid/ezetimibe - Esperion TherapeuticsAlternative Names: ETC 1002/Ezetimibe - Esperion Therapeutics
Latest Information Update: 16 Nov 2015
At a glance
- Originator Esperion Therapeutics
- Class Antihyperlipidaemics; Azetidines; Dicarboxylic acids; Fatty acids; Fluorobenzenes; Propanols; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors; Cholesterol absorption inhibitors; Peroxisome proliferator-activated receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dyslipidaemias